Objective: to investigate the clinicaleffectivenessofprolongedlow-doseurineplasminogenactivator (u-PA) therapy in patients with unstable angina pectoris (UAP).
Directing a team of 50 scientists at Zeneca's labs in Cheshire, U.K., McKillop collected urine samples from employees to isolate EGF and come up with a compound that could effectively block its activity.
McKillop directed a team of 50 scientists at Zeneca's labs in Cheshire, U.K., that collected urine samples from employees to isolate EGF and come up with a compound that could effectively block its activity.